News & Updates
Filter by Specialty:

Survival in mCRPC prolonged with talazoparib–enzalutamide combo
The combination of the PARP inhibitor talazoparib plus the androgen receptor-pathway inhibitor enzalutamide yields a clinically meaningful increase in the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) being treated in the first-line setting when compared with enzalutamide alone, according to final data from the phase III TALAPRO-2 trial.
Survival in mCRPC prolonged with talazoparib–enzalutamide combo
08 Mar 2025
Does using GLP-1 RAs induce suicide in T2D patients?
Patients with type 2 diabetes (T2D) who use glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) appear to have no increased risk of suicidality when compared with the use of dipeptidyl peptidase-4 inhibitors (DPP-4is) or sodium-glucose cotransporter-2 inhibitors (SGLT-2is), a study has found.
Does using GLP-1 RAs induce suicide in T2D patients?
08 Mar 2025
Tislelizumab a new Tx alternative for very high-risk bladder cancer?
In the phase II pilot TRUCE-02 trial, tislelizumab plus low-dose nab-paclitaxel shows promising clinical antitumour activity and is well tolerated in patients with extensive very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy (RC).